Jagsonpal Pharmaceuticals — 360° view

Jagsonpal Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹81 crore and net profit of ₹13 crore for the September 2026 quarter.

Jagsonpal Pharmaceuticals (NSE: JAGSNPHARM) closed at ₹209.27 on 20 Nov 2026, up 1.7% over the past year. Its market capitalisation is ₹1,382 crore and it trades at 29.3 times earnings.

Share price
₹209.27 (20 Nov 2026)
Market cap
₹1,382 Cr (20 Nov 2026)
P/E
29.29 (20 Nov 2026)
Revenue
₹81 Cr (September 2026 quarter)
Net profit
₹13 Cr (September 2026 quarter)
ROCE
22.7% (FY26)
ROE
17.3% (FY26)
Book value
₹36.9 (FY26)
Dividend yield
1.91% (last 12 months to 20 Nov 2026)
52-week high / low
₹264.50 / ₹155.00 (20 Nov 2026)
1-year return
1.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: JAGSNPHARM

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.